Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Rapamycin extends lifespan and attenuates age-related pathologies in mice when administered through diet at 14 parts per million (PPM). Recently, we reported that daily intraperitoneal injection of rapamycin at 8 mg/kg attenuates mitochondrial disease symptoms and progression in the Ndufs4 knockout mouse model of Leigh Syndrome. Although rapamycin is a widely used pharmaceutical agent dosage has not been rigorously examined and no dose-response profile has been established. Given these observations we sought to determine if increased doses of oral rapamycin would result in more robust impact on mTOR driven parameters. To test this hypothesis, we compared the effects of dietary rapamycin at doses ranging from 14 to 378 PPM on developmental weight in control and Ndufs4 knockout mice and on health and survival in the Ndufs4 knockout model. High dose rapamycin was well tolerated, dramatically reduced weight gain during development, and overcame gender differences. The highest oral dose, approximately 27-times the dose shown to extend murine lifespan, increased survival in Ndufs4 knockout mice similarly to daily rapamycin injection without observable adverse effects. These findings have broad implications for the effective use of rapamycin in murine studies and for the translational potential of rapamycin in the treatment of mitochondrial disease. This data, further supported by a comparison of available literature, suggests that 14 PPM dietary rapamycin is a sub-optimal dose for targeting mTOR systemically in mice. Our findings suggest that the role of mTOR in mammalian biology may be broadly underestimated when determined through treatment with rapamycin at commonly used doses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 2×
“…Target Of Rapamycin (mTOR), was the first pharmacological agent reproducibly demonstrated to extend lifespan in multiple organisms including budding yeast, nematodes, flies, and mice (Harrison et al., 2009; Ha and Huh, 2011; Partridge et al., 2011; Choi et al., 2013; Johnson et al., 2013a,b).”
BackgroundMethodmTOR is a key modulator of ageing and age-related disease
Johnson, S. C., Rabinovitch, P. S., & Kaeberlein, M. (2013) · Nature · doi:10.1038/nature11861 · Cited by 1,676 · cited 1×
“All tests were two-tailed and assumed equality of variance, with a p-value less than 0.05 considered statistically significant.”
MethodRapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199
Rapamycin extends murine lifespan but has limited effects on aging
Neff, F., Flores-Dominguez, D., Ryan, D. P., Horsch, M., Schröder, S., Adler, T., Afonso, L. C., Aguilar-Pimentel, J. A., Becker, L., Garrett, L., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67674 · Cited by 374
Ramos, F. J., Chen, S. C., Garelick, M. G., Dai, D.-F., Liao, C.-Y., Schreiber, K. H., MacKay, V. L., An, E. H., Strong, R., Ladiges, W. C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003802 · Cited by 349 · cited 1×
“A similar response was also seen in the Lmna KO mouse model (Ramos et al., 2012).”
ResultSelf-citationYang, S.-B., Tien, A.-C., Boddupalli, G., Xu, A. W., Jan, Y. N., & Jan, L. Y. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.043 · Cited by 242 · cited 1×
“Daily IP injection of rapamycin at 8mg/kg alters neural activity associated with aging (Yang et al., 2012) and robustly reduces whole brain levels of phospho-s6, an indicator of mTOR activity, in Ndufs4 KO and WT animals (Johnson et al., 2013c).”
BackgroundHa, C. W., & Huh, W.-K. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq895 · Cited by 77 · cited 1×
“…Target Of Rapamycin (mTOR), was the first pharmacological agent reproducibly demonstrated to extend lifespan in multiple organisms including budding yeast, nematodes, flies, and mice (Harrison et al., 2009; Ha and Huh, 2011; Partridge et al., 2011; Choi et al., 2013; Johnson et al., 2013a,b).”
BackgroundRapamycin-Induced Glucose Intolerance: Hunger or Starvation Diabetes
Blagosklonny, M. V. (2011) · Cell Cycle · doi:10.4161/cc.10.24.18595 · Cited by 59 · cited 1×
“Intolerance in this assay may reflect an altered metabolic state wherein metabolism is shifted away from glucose utilization, a state of “starvation diabetes” (Blagosklonny, 2011), where animals are not physiologically primed to deal with a sudden, non-physiological increase in blood glucose levels.”
Background
Cited by
mTOR as Regulator of Lifespan, Aging, and Cellular Senescence: A Mini-Review
Weichhart, T. (2018) · Gerontology · doi:10.1159/000484629 · Cited by 596
Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice
Bitto, A., Ito, T. K., Pineda, V. V., LeTexier, N. J., Huang, H. Z., Sutlief, E., Tung, H., Vizzini, N., Chen, B., Smith, K., et al. (2016) · eLife · doi:10.7554/elife.16351 · Cited by 474
Self-citationThe quest to slow ageing through drug discovery
Partridge, L., Fuentealba, M., & Kennedy, B. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0067-7 · Cited by 468
Targeting the biology of aging with mTOR inhibitors
Mannick, J. B., & Lamming, D. W. (2023) · Nature Aging · doi:10.1038/s43587-023-00416-y · Cited by 372
Effect of rapamycin on aging and age-related diseases—past and future
Selvarani, R., Mohammed, S., & Richardson, A. (2021) · GeroScience · doi:10.1007/s11357-020-00274-1 · Cited by 290
Metadata
- Authors
- Johnson, S. C., Yanos, M. E., Bitto, A., Castanza, A., Gagnidze, A., Gonzalez, B., Gupta, K., Hui, J., Jarvie, C., Johnson, B. M., Letexier, N., McCanta, L., Sangesland, M., Tamis, O., Uhde, L., Van Den Ende, A., Rabinovitch, P. S., Suh, Y., & Kaeberlein, M.
- Venue
- Frontiers in Genetics
- Publisher
- Frontiers Media SA
- Published
- 2015-07-22
- Volume
- 6
- Pages
- 247-247
- ISSN
- 1664-8021 (ISSN-L)
- OpenAlex
- W1678888596
- Cited by
- 91
- References
- 8
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice. https://app.cochat.ai/papers/10.3389/fgene.2015.00247
- The paper
- Johnson, S. C., Yanos, M. E., Bitto, A., Castanza, A., Gagnidze, A., Gonzalez, B., Gupta, K., Hui, J., Jarvie, C., Johnson, B. M., Letexier, N., McCanta, L., Sangesland, M., Tamis, O., Uhde, L., Van Den Ende, A., Rabinovitch, P. S., Suh, Y., & Kaeberlein, M. (2015). Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice. Frontiers in Genetics. https://doi.org/10.3389/fgene.2015.00247
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.